我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
DMXAA (Vadimezan) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM, respectively. Phase 3.
| Cas No.: |
117570-53-3 |
| 名称: |
|
| 别名: |
|
| SMILES: |
O=C1C2=CC=CC(CC(O)=O)=C2OC3=C(C)C(C)=CC=C13 |
| 分子式: |
C17H14O4 |
| 分子量: |
282.29 |
| 纯度: |
|
| 保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
|
| In Vivo: |
|
| In Vitro: |
|
| References: |
In DLD-1 human colon carcinoma cells, DMXAA inhibits DT-diaphorase activity without significant effects on the activity of cytochrome b5 reductase and cytochrome P450 reductase. Combination of menadione and DMXAA leads to an increase in the antiproliferat |
| Kinase Assay: |
|
| Cell Assay: |
|
| Animal Administration: |
|
| References: |
|
MSDS
| TITLE |
DOWNLOAD |
| MSDS_3427_DC7404_117570-53-3 |
|
COA
| LOT NO. |
DOWNLOAD |
|
|
询盘
